Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Alipogene Tiparvovec

Gene therapy · Gene replacement · developed by UniQure Biopharma B.V.

Phase 2 Most advanced trial (none active)
QURE Developer
1 Registered trials

What is Alipogene Tiparvovec?

Alipogene tiparvovec (Glybera) is a gene therapy delivered by intramuscular injection at a dose of 1x10^12 gc/kg. It is studied in lipoprotein lipase (LPL) deficiency, also classed as hyperlipoproteinemia type I.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Glybera
Drug type
Gene therapy
Mechanism
Gene replacement
Therapy area
Metabolic
Developer
UniQure Biopharma B.V. (QURE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
20OK4AFR4Y

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT02904772 Phase 2 LPL Deficiency Withdrawn QURE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

LPL Deficiency

More from UniQure Biopharma B.V.

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the QURE page.

Follow QURE, the company behind Alipogene Tiparvovec

See QURE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

QURE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.